Using Recursive Logistic Regression to Develop a Patient-reported Outcome in Non-cystic Fibrosis Bronchiectasis by Wheldon, MC et al.
Using Recursive Logistic Regression
to Develop a Patient-Reported Outcome
in Non-Cystic Fibrosis Bronchiectasis
ORSNZ+NZSA Joint Conference, Christchurch, November 2015
Mark C. Wheldon1,2
Alain C. Vandal1,3, Anne-Ce´cile Bourien4, Lata Jayaram5,
Noel Karalus6, Cecilia Tong2, Hans Hockey7, and Conroy Wong3
1Auckland University of Technology 2Middlemore Clinical Trials 3Counties Manukau
Health 4ENSAI France 5Monash Health Sleep Lab 6Waikato District Health
Board 7Biometrics Matters Ltd.
EMBRACE Trial
This work is an extension to the trial: Wong, C., et al. Lancet (2012)
vol. 380, pp. 660–7
Articles
660 www.thelancet.com   Vol 380   August 18, 2012
Lancet 2012; 380: 660–67
See Comment page 627
Department of Respiratory 
Medicine (C Wong FRACP), 
Centre for Clinical Research and 
eﬀ ective practice (C Tong RN), 
and Department of 
Microbiology (L Storey BSc), 
Middlemore Hospital, Counties 
Manukau District Health Board, 
Auckland, New Zealand; 
Department of Respiratory 
Medicine, Monash Medical 
Centre, Clayton, VIC, Australia 
(L Jayaram FRACP); Department 
of Respiratory Medicine, 
Waikato Hospital, Waikato 
District Health Board, Hamilton, 
New Zealand (N Karalus FRACP, 
C Tuﬀ ery BN); 85 Totara Road, 
Whenuapai, Auckland, 
New Zealand (T Eaton FRACP); 
Biometrics Matters Ltd, 
Hamilton, New Zealand 
(H Hockey MSc); Department of 
Radiology (D Milne FRANZCR) 
and Department of Respiratory 
Medicine (W Fergusson BHSc, 
P Sexton FRACP), Auckland City 
Hospital, Auckland District 
Health Board, Auckland, New 
Zealand; and School of 
Population Health, University 
of Auckland, Auckland, 
New Zealand (Prof T Ashton PhD)
Correspondence to:
Dr Conroy Wong, Department 
of Respiratory Medicine, 
Middlemore Hospital, Counties 
Manukau District Health Board, 
Otahuhu, Auckland 2025, 
New Zealand 
cawong@middlemore.co.nz
Azithromycin for prevention of exacerbations in non-cystic 
ﬁ brosis bronchiectasis (EMBRACE): a randomised, 
double-blind, placebo-controlled trial
Conroy Wong, Lata Jayaram, Noel Karalus, Tam Eaton, Cecilia Tong, Hans Hockey, David Milne, Wendy Fergusson, Christine Tuﬀ ery, Paul Sexton, 
Louanne Storey, Toni Ashton
Summary
Background Azithromycin is a macrolide antibiotic with anti-inﬂ ammatory and immunomodulatory properties. We 
tested the hypothesis that azithromycin would decrease the frequency of exacerbations, increase lung function, and 
improve health-related quality of life in patients with non-cystic ﬁ brosis bronchiectasis.
Methods We undertook a randomised, double-blind, placebo-controlled trial at three centres in New Zealand. Between 
Feb 12, 2008, and Oct 15, 2009, we enrolled patients who were 18 years or older, had had at least one pulmonary 
exacerbation requiring antibiotic treatment in the past year, and had a diagnosis of bronchiectasis deﬁ ned by high-
resolution CT scan. We randomly assigned patients to receive 500 mg azithromycin or placebo three times a week for 
6 months in a 1:1 ratio, with a permuted block size of six and sequential assignment stratiﬁ ed by centre. Participants, 
research assistants, and investigators were masked to treatment allocation. The coprimary endpoints were rate of event-
based exacerbations in the 6-month treatment period, change in forced expiratory volume in 1 s (FEV1) before broncho-
dilation, and change in total score on St George’s respiratory questionnaire (SGRQ). Analyses were by intention to treat. 
This study is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12607000641493.
Findings 71 patients were in the azithromycin group and 70 in the placebo group. The rate of event-based exacerbations 
was 0·59 per patient in the azithromycin group and 1·57 per patient in the placebo group in the 6-month treatment 
period (rate ratio 0·38, 95% CI 0·26–0·54; p<0·0001). Prebronchodilator FEV1 did not change from baseline in the 
azithromycin group and decreased by 0·04 L in the placebo group, but the diﬀ erence was not signiﬁ cant (0·04 L, 
95% CI –0·03 to 0·12; p=0·251). Additionally, change in SGRQ total score did not diﬀ er between the azithromycin 
(–5·17 units) and placebo groups (–1·92 units; diﬀ erence –3·25, 95% CI –7·21 to 0·72; p=0·108).
Interpretation Azithromycin is a new option for prevention of exacerbations in patients with non-cystic ﬁ brosis 
bronchiectasis with a history of at least one exacerbation in the past year.
Funding Health Research Council of New Zealand and Auckland District Health Board Charitable Trust.
Introduction
Bronchiectasis is a disorder characterised by neutrophilic 
airway inﬂ ammation, chronic bacterial infection, and 
recurrent pulmonary exacerbations.1 Patients with bron-
chiectasis can have a disabling cough with production of 
large amounts of sputum, progressive decline in lung 
function,2 impaired quality of life,3,4 and increased 
mortality.5,6 Exacerbations occur at rates of 1·5–6·5 per 
patient per year,7,8 and are associated with an increased risk 
of admission and readmission to hospital, and high health-
care costs.9
The prevalence of bronchiectasis in most adult popu-
lations worldwide is unknown. With the widespread 
availability of modern diagnostic techniques such as high-
resolution CT scanning, bronchiectasis is in creasingly 
being recognised. In the USA, the number of bronchi-
ectasis-associated admissions increased by 2–3% per year 
between 1993 and 2006, and the mean annual rate of 
admission in this period was 16·5 per 100 000 people.9 A 
further study10 showed that the prevalence of bronchiectasis 
increased by 8·7% per year between 2000 and 2007.
Few evidence-based treatments are available for the 
prevention and management of exacerbations and more 
are urgently needed.11 Macrolide antibiotics have anti-
inﬂ ammatory and immunomodulatory prop erties in 
addition to their antibacterial properties.12 In the Eﬀ ective-
ness of Macrolides in patients with BRonchi ectasis using 
Azithromycin to Control Exacerbations (EMBRACE) trial, 
we tested whether azithromycin de creases the frequency 
of exacerbations, increases lung function, and improves 
health-related quality of life in patients with non-cystic 
ﬁ brosis bronchiectasis.
Methods
Study design and participants
We undertook a randomised, double-blind, placebo-
controlled trial at three centres in New Zealand between 
Feb 12, 2008, and Oct 15, 2009. Patients were eligible for 
inclusion in the study when they were 18 years or older, 
had had at least one pulmonary exacerbation requiring 
antibiotic treat ment in the past year, and had a diagnosis 
of bron chiectasis deﬁ ned by high-resolution CT scan. All 
Background 1
Bronchiectasis
I Respiratory condition.
I Caused by chronic infection of
airways.
I Signs and symptoms:
I chronic inflammation of airways
I bacterial infection
I recurring exacerbations
I increased mortality.
I disabling cough
I production of large quantities of
sputum
I reduced quality of life.
Background 2
EMBRACE Design
Objectives Assess the effect of azithromycin on health-related quality
of life and lung function in patients 18–80 years with
bronchiectasis (diagnosed by CT scan).
Design Multicenter (3), double-blind, placebo-controlled, parallel
group (1:1), 141 pts total.
Intervention 500mg azithromycin capsule vs. placebo, 3 days per week,
for 6 months.
Follow-up 6 months (treatment period) and 12 months.
1◦ Endpoints i) Rate of Event Based Exacerbations (EBEs) over 6 mo.
treatment period;
ii) Change in St. George’s Respiratory Questionnaire (tot.
score); (+ others).
2◦ Endpoints Symptom scores for: sputum purulence, sputum volume,
dyspnoea; (+ others).
Background 3
Exacerbations
I Exacerbations and symptom scores recorded prospectively in patient
diaries.
I Each patient-day judged exacerbation or no exacerbation.
I Key symptoms of an exacerbation are
I Sputum volume
I Sputum purulence (colour)
I Dyspnoea (shortness of breath, coughing).
I Two types: Event-based (EBE) and Symptom-based (SBE).
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Figure : Diarized days by Event-based exacerbations status for each EMBRACE location, all
patient-days.
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Exacerbations
EBE is Physician-Determined
I EBEs require treatment with antibiotics.
I Ascertainment of EBE requires contact with clinician.
SBE is Patient-Determined
I SBEs are adjudicated using daily symptom diaries completed by
patients.
I Patients have input into evaluation of their own health status.
I This is a patient-reported outcome.
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Manually Adjudicated SBEs (manSBEs)
I Adjudication of SBEs originally done by manual review of diaries.
I This was laborious and time-consuming.
I Eventually abandoned.
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Goals
Automatically Adjudicate SBEs
I Automatically adjudicate SBEs.
I In the process, revisit the definition ⇒ New SBE.
Validate New SBE Against EBE
I Estimate performance of new SBE as a predictor of EBE.
I Assess treatment sensitivity of new SBE.
Background 8
(Goals II)
Jointly Validate Against Patient-Reported Wellbeing
I Patients also reported their general wellbeing in the diaries.
I Assess, and improve, performance of new SBE as a measure of
wellbeing.
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Method
Data
I Observed ∼ 50 000 patient-days observed on 141 patients across 3
centres over 6 months.
I Symptoms: patients rated severity of
I Sputum purulence, sputum volume, dyspnoea
on a validated 5-point scale, 0 “no symptom”→ 4 “very much”.
I Wellbeing: “I feel well”, 1 “strongly agree”→ 5 “strongly disagree”.
Table : Example data
Symptoms
Pat. Day EBE SP SV DY Well B SBE
1 0 0 1 1 1 1 ↑
1 1 1 3 3 4 1 ↑
...
...
...
...
...
...
... Adjudicated
1 17 1 2 1 5 2 ↓
1 18 0 1 0 0 3 ↓
...
...
...
...
...
...
... ↓
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Method 10
Goal is a Model for Prediction
I Statistical goal is a model to predict a time-ordered, clustered,
binary outcome, EBEi,t .
I ⇒ propose a model (somehow!).
I Verify it has good predictive power.
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Model Selection
I Based on manSBE procedure, decided to use symptom scores and
EBE at an earlier time-point (EBEi,t−δ, 0 < δ) as explanatory
variables.
I Used a GLMM, logit link, with random intercepts for patient.
EBEi,t ∼ Bern
(
pi,t
)
logit pi,t |
(
x, bi
)
= x′i,tβ + bi
bi ∼ Normal(0, τ 2)
I xi,t contains symptom scores averaged over two time windows
(contemporaneous, earlier), and EBEi,t−δ:
x′i,t =
[
1 SVi,cont. SPi,cont. DYi,cont.
SVi,earl. SPi,earl. DYi,earl. EBEi,t−δ
]
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Model Selection
I Dichotomize using a threshold, c, such that sensitivity = specificity:
SBE ≡ ÊBEi,t =
{
1 if p̂i,t > c
0 if p̂i,t ≤ c
Design parameters are: x, δ, c .
x, δ Time windows, averaging method, EBE offset chosen to
give good in-sample predictive performance (using AUC).
δ = 5
c Two-stage estimation of c.
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Model Performance
Two-fold Cross-validation
I Split data into a training set and a hold-out set for validation.
I Randomly select 70 percent of the patients and allocate all their
observations to the training set.
I The remainder go into the hold-out set.
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Prospective Prediction
I The selected model is retrospective in that today’s prediction
depends on earlier GP-adjudicated EBEs.
logit pi,t |
(
EBEi,t−5, ·
)
= x′iβ + bi (1)
I We want a prospective model based on patient-reported outcomes
⇒ must use its own earlier predictions.
logit pi,t |
(
ÊBEi,t−5, ·
)
= z′iβ + bi (2)
I (1) is a recursive logistic model (Bonney, 1986, 1987).
I To fit (2), a sequential procedure was used.
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Sequential Approach
1. Initialize by generating retrospective predictions, ÊBE
[ret]
i,1 , . . . ,
ÊBE
[ret]
i,5 , using β̂ and threshold, c
[ret], from the retrospective model.
Using the training set:
2. Sequentially generate prospective predictions ÊBE
[pro]
i,6 , ÊBE
[pro]
i,7 , . . . .
I Use “population level” predictions
I Use c [ret] to threshold the predicted probabilities (we have to because
this is the only c currently available).
3. Re-estimate the binary threshold → c [pro].
Using the hold-out set:
4. Repeat 2 using c [pro].
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Method Overview
1. Build a retrospective prediction model for EBEt using
I symptom scores
I GP-adjudicated EBE status at times t ∈ [t − δ, t0).
2. Convert to a “prospective” model for EBEt using
I retrospective design
I patient-report-derived EBE status at times t ∈ [t − δ, t0).
3. Estimate its predictive performance.
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Results
Dataset Model c (used) c (Opt.) Sens. (%) Spec. (%)
Training Retro. 0.093 0.093 90 92
Prosp. 0.093 0.048 76 88
Prosp. 0.048 0.048 83 83
Hold-out Prosp. 0.048 — 90 79
I Our prospective SBE predictor,
I misses 10 percent of the EBEs (1 in 10)
I calls an EBE 21 percent of time there isn’t one (1 in 5).
I Relative to using the whole dataset,
I Estimated sensitivity equal,
I Specificity is 86 percent (↓ 13 percentage points).
Results 18
Results
Dataset Model c (used) c (Opt.) Sens. (%) Spec. (%)
Training Retro. 0.093 0.093 90 92
Prosp. 0.093 0.048 76 88
Prosp. 0.048 0.048 83 83
Hold-out Prosp. 0.048 — 90 79
I Our prospective SBE predictor,
I misses 10 percent of the EBEs (1 in 10)
I calls an EBE 21 percent of time there isn’t one (1 in 5).
I Relative to using the whole dataset,
I Estimated sensitivity equal,
I Specificity is 86 percent (↓ 13 percentage points).
Results 18
Results
Dataset Model c (used) c (Opt.) Sens. (%) Spec. (%)
Training Retro. 0.093 0.093 90 92
Prosp. 0.093 0.048 76 88
Prosp. 0.048 0.048 83 83
Hold-out Prosp. 0.048 — 90 79
I Our prospective SBE predictor,
I misses 10 percent of the EBEs (1 in 10)
I calls an EBE 21 percent of time there isn’t one (1 in 5).
I Relative to using the whole dataset,
I Estimated sensitivity equal,
I Specificity is 86 percent (↓ 13 percentage points).
Results 18
Results
Dataset Model c (used) c (Opt.) Sens. (%) Spec. (%)
Training Retro. 0.093 0.093 90 92
Prosp. 0.093 0.048 76 88
Prosp. 0.048 0.048 83 83
Hold-out Prosp. 0.048 — 90 79
I Our prospective SBE predictor,
I misses 10 percent of the EBEs (1 in 10)
I calls an EBE 21 percent of time there isn’t one (1 in 5).
I Relative to using the whole dataset,
I Estimated sensitivity equal,
I Specificity is 86 percent (↓ 13 percentage points).
Results 18
Patient-Reported Wellbeing
I Patients also reported wellbeing each day using a 1–5 scale.
I Ultimately, we’re interested in a patient-reported outcome that is
sensitive to both changes in physical state and patient-reported
wellbeing.
I How is our new definition of SBE associated with wellbeing?
I Do we get “closer” to wellbeing with SBE rel. to EBE?
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Wellbeing and SBE
Figure : Wellbeing and SBE linear predictor for patient no. 101.
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Wellbeing and SBE
Figure : Wellbeing and SBE linear predictor for patient no. 147.
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Wellbeing and SBE
I Weighted Pearson correlation between wellbeing and the linear
predictor from the SBE model is ρ̂ = 0.33.
I Future: combine the SBE prediction model with a similar one for
wellbeing.
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Summary
I Exacerbations are an outcome of interest in the study of
bronchiectasis.
I Ascertainment of event-based exacerbations (EBEs) requires clinical
assessment.
I Symptom-based exacerbations (SBEs) are ascertained from
patient-reported symptom scores and exacerbation history, coded “by
hand”.
I We used logistic regression to develop an “automatic” coding
scheme; changes in symptoms that are associated with changes in
physical state (EBE).
I As a classifier of EBE the performance was quite good (sens. 90%,
spec. 79%).
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